A5001137608- CRISPR and Genetic Engineering
- Pancreatic and Hepatic Oncology Research
- DNA Repair Mechanisms
- Molecular Biology Techniques and Applications
- BRCA gene mutations in cancer
- Animal Genetics and Reproduction
- Pluripotent Stem Cells Research
- Breast Lesions and Carcinomas
- Cancer, Hypoxia, and Metabolism
- Radiomics and Machine Learning in Medical Imaging
- Genetics, Bioinformatics, and Biomedical Research
- Cancer Mechanisms and Therapy
- Chromosomal and Genetic Variations
- Biomedical Text Mining and Ontologies
- Biochemical and Molecular Research
- Cancer-related Molecular Pathways
- RNA modifications and cancer
- Breast Cancer Treatment Studies
- Genetic and rare skin diseases.
- Innovation Policy and R&D
- Cancer Immunotherapy and Biomarkers
- Lymphoma Diagnosis and Treatment
- Intellectual Property and Patents
- Advanced Proteomics Techniques and Applications
- Clinical Reasoning and Diagnostic Skills
Barts Health NHS Trust
2024
Royal London Hospital
2024
Wellcome Sanger Institute
2007-2022
University of Cambridge
2007-2009
Addenbrooke's Hospital
2007-2009
Peterborough City Hospital
2009
Babraham Institute
2007
The Gurdon Institute
2007
Institute of Cancer Research
2002-2003
Breast Cancer Now
2003
MicroRNAs are a class of small RNAs that increasingly being recognized as important regulators gene expression. Although hundreds microRNAs present in the mammalian genome, genetic studies addressing their physiological roles at an early stage. We have shown mice deficient for bic/microRNA-155 immunodeficient and display increased lung airway remodeling. demonstrate requirement function B T lymphocytes dendritic cells. Transcriptome analysis bic/microRNA-155-deficient CD4+ cells identified...
Abstract Purpose: To determine the efficacy of AZD0530, an orally active small molecule Src inhibitor, in human pancreatic cancer xenografts and to seek biomarkers predictive activity. Experimental Design: Sixteen patient-derived from PancXenoBank collection at Johns Hopkins were treated with AZD0530 (50 mg/kg/day, p.o.) for 28 days. Baseline gene expression profiles differently expressed genes 16 tumors by Affymetrix U133 Plus 2.0 array used predict sensitivity independent group eight using...
Abstract Despite the introduction of novel targeted therapies, chemotherapy still remains primary treatment for metastatic melanoma in poorly funded healthcare environments or case disease relapse, with no reliable molecular markers progression-free survival (PFS) available. As primarily eliminates cancer cells by apoptosis, we here evaluated if expression key apoptosis regulators (Bax, Bak, Bcl-2, Bcl-xL, Smac, Procaspase-9, Apaf-1, Procaspase-3 and XIAP) allows prognosticating PFS stage...
Carriers of mutations in the BRCA2 gene have a high risk developing breast and other cancers. The gene, which is located on human chromosome 13, encodes very large protein only poorly understood function. To define regions sequence conservation highlight potentially functionally important domains, we cloned characterized chicken first non-mammalian to be described. organized similarly but more compact localized subtelomeric region 1q, within that contains genes from 13. 3399 amino acids,...
Immunohistochemistry is an indispensable tool in human pathology enabling immunophenotypic characterization of tumor cells. Immunohistochemical analyses mouse models hematopoietic neoplasias have become important aspect for comparison murine entities with their counterparts. The aim this study was to establish a diagnostic antibody panel analysis lymphomas/leukemias, useful formalin-fixed/paraffin-embedded tissue. Overall, 48 antibodies (4 rabbit monoclonal, 12 polyclonal, 2 goat 11 rat, and...
Genetic mosaics produced by FLP/FRT induced mitotic recombination have been widely used in Drosophila to study gene function development. Recently, the Cre/loxP system has applied induce mouse embryonic stem cells and many adult tissues. We this strategy generate a previously undescribed p53 model which expression of ubiquitously expressed recombinase heterozygous knockout animal produces recombinant clones homozygous for mutation. The induction loss heterozygosity few an otherwise normal...
Heterozygous carriers of mutations in the BRCA2 gene have a high risk developing breast and other cancers. In these individuals, appears to act as tumour suppressor gene, that loss wild type allele is frequently observed within tumours, leading function. Because functions DNA repair via homologous recombination, this leads genomic instability. However, it unclear whether stochastic or if heterozygosity for mutation carries phenotype contributes tumorigenic progression. Here we demonstrate...
The European Radiobiology Archives (ERA), together with corresponding Japanese and American databases, hold data from nearly all experimental animal radiation biology studies carried out between 1960 1998, involving more than 300,000 animals. Federal Office for Radiation Protection, the University of Cambridge have undertaken to transfer existing ERA archive a web-based database maximize its usefulness scientific community bring coding structure this legacy into congruence currently accepted...
Large-scale cancer genome projects will soon be able to sequence many genomes comprehensively identify genetic changes in human cancer. Genome-wide association studies have also identified putative associated loci. Functional validation of these mutations vivo is becoming a challenge. We describe here DNA transposon-based platform that permits us explore the oncogenic potential mouse. Briefly, promoter-less gene cDNAs were first cloned into Sleeping Beauty (SB) transposons. transposition...
GNAS/Gnas encodes Gsα that is mainly biallelically expressed but shows imprinted expression in some tissues. In Albright Hereditary Osteodystrophy (AHO) heterozygous loss of function mutations GNAS can result ectopic ossification tends to be superficial and attributable haploinsufficiency Gsα. Oed-Sml a point missense mutation exon 6 the orthologous mouse locus Gnas. We report here both late onset occurrence benign cutaneous fibroepithelial polyps Oed-Sml. These phenotypes are seen on...
Abstract The generation of new mouse models human disease is accelerating rapidly, due to the completion whole‐genome sequencing efforts and technological advances in manipulation genome. We sought investigate manpower issues provision histopathology expertise for functional genomics compared this perceived demand from principal investigators (PIs). Through European Commission (EC)‐funded PRIME pathology training initiative, two questionnaires were devised collect information pathologists...
N′-ethyl- N′-nitrosourea (ENU) is a powerful germline mutagen used in conjunction with phenotype-driven screens to generate novel mouse mutants. ENU also induces genetic lesions somatic cells and dosage requires optimization between maximum mutation rate versus induced sterility tumourigenesis that compromise the welfare fecundity of ENU-treated males. Here, we present our experience BALB/cAnNCrl C57BL/6J mice terms pathology by its impact on breeding. In both strains, morbidity mortality...
Aims Atypical ductal hyperplasia and flat epithelial atypia (FEA) have defined diagnostic criteria, yet there is variation in the interpretation of these particularly when present a background columnar cell lesions (CCLs). This study focuses upon cases which are especially challenging or difficult to classify reproducibly according existing criteria. Methods results Thirteen breast pathology experts were asked 10 with CLLs as atypical non‐atypical. Interobserver agreement was calculated....
The European Commission's revised technology transfer regime: an ‘evolution’ giving both licensors and licensees reasons to reconsider their approach licensing arrangements settlement of IP disputes.
Supplementary Data from Antitumor Effects and Biomarkers of Activity AZD0530, a Src Inhibitor, in Pancreatic Cancer
<div>Abstract<p><b>Purpose:</b> To determine the efficacy of AZD0530, an orally active small molecule Src inhibitor, in human pancreatic cancer xenografts and to seek biomarkers predictive activity.</p><p><b>Experimental Design:</b> Sixteen patient-derived from PancXenoBank collection at Johns Hopkins were treated with AZD0530 (50 mg/kg/day, p.o.) for 28 days. Baseline gene expression profiles differently expressed genes 16 tumors by Affymetrix...